Farther Finance Advisors LLC Has $32,000 Position in Koninklijke Philips N.V. $PHG

Farther Finance Advisors LLC reduced its stake in shares of Koninklijke Philips N.V. (NYSE:PHG) by 33.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,314 shares of the technology company’s stock after selling 648 shares during the period. Farther Finance Advisors LLC’s holdings in Koninklijke Philips were worth $32,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Bessemer Group Inc. grew its holdings in shares of Koninklijke Philips by 2,935.4% during the 1st quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company’s stock valued at $51,000 after acquiring an additional 1,908 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Koninklijke Philips by 1,170.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,439 shares of the technology company’s stock valued at $62,000 after buying an additional 2,247 shares during the last quarter. Allworth Financial LP raised its position in shares of Koninklijke Philips by 16.2% during the first quarter. Allworth Financial LP now owns 4,638 shares of the technology company’s stock valued at $115,000 after buying an additional 645 shares during the last quarter. Wealthquest Corp acquired a new position in Koninklijke Philips in the first quarter worth about $116,000. Finally, Geneos Wealth Management Inc. raised its position in Koninklijke Philips by 45.5% in the first quarter. Geneos Wealth Management Inc. now owns 4,755 shares of the technology company’s stock worth $121,000 after purchasing an additional 1,488 shares in the last quarter. 13.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on PHG. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Koninklijke Philips in a research note on Saturday, September 27th. Wall Street Zen lowered shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Koninklijke Philips Stock Down 0.7%

Koninklijke Philips stock opened at $27.83 on Wednesday. The company has a market cap of $26.80 billion, a P/E ratio of 146.49, a price-to-earnings-growth ratio of 0.74 and a beta of 0.82. Koninklijke Philips N.V. has a 1-year low of $21.48 and a 1-year high of $32.62. The company has a fifty day simple moving average of $27.48 and a 200 day simple moving average of $25.21. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.69.

Koninklijke Philips (NYSE:PHG) last released its earnings results on Tuesday, July 29th. The technology company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.12. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $4.35 billion. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. Research analysts anticipate that Koninklijke Philips N.V. will post 1.63 earnings per share for the current fiscal year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.